Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17720551 | 0.87 | CA1 (0.30) | CA1CA2CA9 | |
| SCHEMBL24862293 | 0.85 | — | — | |
| SCHEMBL16317392 | 0.84 | CA1 (0.31) | CA1CA2CA9HTT | |
| SCHEMBL17878002 | 0.82 | ACHE (0.30) | — | |
| SCHEMBL2700574 | 0.77 | — | — | |
| SCHEMBL30100857 | 0.77 | — | — | |
| SCHEMBL29992310 | 0.77 | HTT (0.34) | HTT | |
| SCHEMBL10060674 | 0.75 | CA1 (0.31) | CA1CA2CA9 | |
| SCHEMBL30100906 | 0.73 | — | — | |
| SCHEMBL28469373 | 0.73 | MEN1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0994128-B1 | Process and iron-based catalyst composition for the production of syndiotactic 1,2-polybutadiene | BRIDGESTONE CORP (JP) | 2007-08-01 | — | — | EP | claimed |
| US-6620760-B2 | Coordination catalyst | BRIDGESTONE CORPORATION (JP) | 2003-09-16 | — | — | US | claimed |
| US-20260128377-A1 | ELECTROLYTE WITH HIGH LIFSI CONCENTRATION | ARKEMA FRANCE (FR) | 2026-05-07 | — | — | US | disclosed |
| US-12280364-B2 | Complex compound and method for manufacturing the same | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2025-04-22 | — | — | US | disclosed |
| US-20250002818-A1 | CLEANING SOLUTION, METHOD FOR CLEANING SUBSTRATE, AND METHOD FOR MANUFACTURING SEMICONDUCTOR | TOKYO OHKA KOGYO CO., LTD. (JP) | 2025-01-02 | — | — | US | disclosed |
| CN-114423774-B | Ascaroside derivatives and methods of use | 加利福尼亚技术学院 | 2024-11-08 | — | — | CN | disclosed |
| US-20240356083-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH PHOSPHORUS CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORP (US) | 2024-10-24 | — | — | US | disclosed |
| US-11961967-B2 | Silicon-based energy storage devices with phosphorus containing electrolyte additives | ENEVATE CORPORATION (US) | 2024-04-16 | — | — | US | disclosed |
| US-11916198-B2 | Fast-charging lithium ion batteries with electrolytes that do not react on the anodes | StoreDot Ltd. (IL) | 2024-02-27 | — | — | US | disclosed |
| US-11845770-B2 | Ascaroside derivatives and methods of use | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | AEQUOR, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| EP-0994129-A1 | Iron-based catalyst composition and process for producing syndiotactic 1,2-polybutadiene | Bridgestone Corporation (JP) | 2000-04-19 | — | — | EP | disclosed |
| EP-0994127-A1 | Method of preparing syndiotactic 1,2-polybutadiene with a chromium-based catalyst system | Bridgestone Corporation (JP) | 2000-04-19 | — | — | EP | disclosed |
| EP-0994128-A1 | Process and iron-based catalyst composition for the production of syndiotactic 1,2-polybutadiene | Bridgestone Corporation (JP) | 2000-04-19 | — | — | EP | disclosed |
| US-5919875-A | ORGANOALUMINUM HYDRIDE, ORGANIC HYDROGEN PHOSPHITE | BRIDGESTONE CORPORATION (JP) | 1999-07-06 | — | — | US | disclosed |
| US-5426206-A | Stereospecific synthesis of aldols | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-06-20 | — | — | US | disclosed |
| EP-0529655-B1 | 2-Piperidinecarboxylic acid derivative, oncogene suppressor and agent for obtaining revertants | MEIJI SEIKA KAISHA (JP) | 1995-05-24 | — | — | EP | disclosed |
| WO-1994026692-A1 | BICYCLIC AMIDE DERIVATIVES AND THEIR USE AS MUSCLE RELAXANTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-11-24 | — | — | WO | disclosed |
| US-5334723-A | Antitumor agents | MEIJI SEIKA KAISHA, LTD. (JP) | 1994-08-02 | — | — | US | disclosed |
| EP-0529655-A1 | 2-Piperidinecarboxylic acid derivative, oncogene suppressor and agent for obtaining revertants | MEIJI SEIKA KAISHA LTD. (JP) | 1993-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845770-B2 | Ascaroside derivatives and methods of use | TLR4, TLR7, MYD88 | CA1 4040/4885CA2 4077/4885CA9 3412/4885 |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | DDT, AS3MT, GPX4 | CA1 2715/4885CA2 738/4885CA9 1139/4885 |
| US-20260128377-A1 | ELECTROLYTE WITH HIGH LIFSI CONCENTRATION | CCNI, FLI1, FOS | CA1 47/4885CA2 130/4885CA9 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.